科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

交易中 07-23 13:44:35

14.730

-0.260

-1.73%

最高14.900	最低14.480	成交量115.16万
今开14.900	昨收14.990	日振幅2.80%
总市值87.50亿	流通市值87.50亿	总股本5.94亿
成交额1,689万	换手率0.19%	流通股本5.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":14.73,"timestamp":1784785435006,"preClose":14.99,"halted":0,"volume":1151600,"delay":0,"changeRate":-0.017344896597731807,"floatShares":594000000,"shares":594000000,"eps":-0.177264,"marketStatus":"交易中","change":-0.26,"latestTime":"07-23 13:44:35","open":14.9,"high":14.9,"low":14.48,"amount":16891908,"amplitude":0.028019,"askPrice":14.73,"askSize":500,"bidPrice":14.68,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.182,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784794200000},"marketStatusCode":2,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":14.99,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.521964,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"1146432966","title":"科济药业-B于7月17日回购322,500股股份，总额约498.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146432966","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146432966?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:42","pubTimestamp":1784299332,"startTime":"0","endTime":"0","summary":"2026年7月17日，科济药业-B发布翌日报表公告，披露其在香港联交所场内回购股份并进行已发行股份变动。根据公告，科济药业-B于2026年7月17日回购322,500股普通股，约占此前已发行股份总数的0.054%。此次回购每股价格区间介于15.28港元至15.68港元，合计耗资约498.12万港元，相关回购股份拟予以注销。本次发行后，公司于2026年7月17日的已发行股份数为594,228,998股，库存股份则保持在7,228,000股，合计达601,456,998股。公司于2026年5月22日获得回购授权，获准回购最多57,096,024股股票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科济药业-B于7月17日回购322,500股股份，总额约498.12万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289463","title":"科济药业-B(02171)7月17日斥资498.12万港元回购32.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289463","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652289463?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:38","pubTimestamp":1784299082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，于2026年7月17日斥资498.12万港元回购32.25万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02171","BK1574","BK1585","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161662799","title":"异动解读｜科济药业-B盘中下跌6.03%，报15.91港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161662799","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161662799?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:03","pubTimestamp":1784253795,"startTime":"0","endTime":"0","summary":"7月17日，科济药业-B盘中下跌6.03%，报15.91港元/股，成交额1668.33万港元。科济药业-B所在的生物科技行业整体走弱，个股中，康方生物跌8.5%，三生制药跌7.65%，科伦博泰生物跌4.69%，信达生物跌3.03%，百济神州跌2.36%。科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司，主营业务为开发CAR-T细胞疗法，覆盖血液恶性肿瘤、实体瘤及自身免疫性疾病领域，主要产品包括赛恺泽、舒瑞基奥仑赛注射液及通用型CAR-T细胞产品。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651490622","title":"港股异动 | 科济药业-B(02171.HK)涨超7% 恺力美®通过2026年商保创新药目录初步形式审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2651490622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651490622?lang=zh_cn&edition=full","pubTime":"2026-07-16 10:43","pubTimestamp":1784169837,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1587","BK1161","BK1574","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194794077","title":"异动解读｜科济药业-B盘中上涨5.51%，恺力美术后巩固治疗初步积极结果获ESMO年会壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1194794077","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194794077?lang=zh_cn&edition=full","pubTime":"2026-07-16 10:27","pubTimestamp":1784168854,"startTime":"0","endTime":"0","summary":"消息面上，公司于7月15日宣布，恺力美在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球首个获批上市的实体瘤CAR-T细胞治疗产品，此次术后巩固治疗方向的探索进一步拓展了其适应症潜力，市场情绪延续利好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651843550","title":"港股异动 | 科济药业-B(02171)涨超6% 恺力美®研究结果即将于2026年ESMO年会进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2651843550","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651843550?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:49","pubTimestamp":1784083754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨超6%，截至发稿，涨5.94%，报16.42港元，成交额3262.85万港元。消息面上，7月15日，据科济药业官微消息，公司宣布，恺力美在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验初步积极结果已被2026年欧洲肿瘤内科学会年会接受进行壁报展示。科济药业表示，截至7月15日，CT041-CG4010自2025年5月启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","KCAI","BK4585","BK1161","02171","BK1574","BK1587","BK4588","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651480824","title":"科济药业-B(02171.HK)：恺力美?的研究结果摘要已获2026年ESMO年会接受进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2651480824","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651480824?lang=zh_cn&edition=full","pubTime":"2026-07-15 08:27","pubTimestamp":1784075222,"startTime":"0","endTime":"0","summary":"格隆汇7月15日丨科济药业-B宣布，恺力美?在中国开展的针对胃╱食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起的临床试验初步积极结果已被2026年欧洲肿瘤内科学会年会接受进行壁报展示。摘要将于2026年10月19日(星期一)欧洲中部夏令时间00:05于ESMO官网公布。治疗的参与者均未发生胃癌术后复发或转移。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260715/32307701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","BK1587","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106059420","title":"科济药业-B（02171）：凯力美®术后巩固治疗初步积极结果获ESMO 2026年会壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1106059420","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106059420?lang=zh_cn&edition=full","pubTime":"2026-07-15 08:05","pubTimestamp":1784073928,"startTime":"0","endTime":"0","summary":"2026年7月15日，科济药业-B发布自愿公告称，公司自主研发的全球同类首创Claudin18.2靶向自体CAR-T细胞治疗产品凯力美在中国开展的术后巩固治疗研究者发起临床试验初步结果已被2026年欧洲肿瘤内科学会年会接纳，拟以壁报形式展示。相关摘要将于2026年10月19日00:05在ESMO官网公布。该IIT试验自2025年5月启动入组。截至公告发布日，所有接受凯力美治疗的受试者均未发生胃癌术后复发或转移。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109791199","title":"科济药业-B 7月13日回购118,500股，涉资约182.44万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109791199","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109791199?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:21","pubTimestamp":1783948891,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司于2026年7月13日公告称，公司当日于香港联交所进行股份回购，数量合计118,500股，占公司已发行股本约0.02%。回购价格介乎每股15.33港元至15.45港元，合计耗资约HKD 182.44万。根据公告，本次回购股份将予注销。公司于2026年5月22日获得了股东大会通过的股份购回授权，总额度为57,096,024股，截至目前已根据该授权累计回购股份388,500股，占授权时已发行股票总数约0.068%。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科济药业-B 7月13日回购118,500股，涉资约182.44万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651261114","title":"科济药业-B(02171.HK)7月13日斥资182.44万港元回购11.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651261114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651261114?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:16","pubTimestamp":1783948618,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1585","BK1587","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650874942","title":"佐力药业：公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650874942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650874942?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583479,"startTime":"0","endTime":"0","summary":"证券之星消息，佐力药业07月09日在投资者关系平台上答复投资者关心的问题。这是贵司参股的科济药业，贵司按目前股价已大赚了3亿多？介绍科济药业抗癌？公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份，属于其他权益工具投资，其公允价值变动计入公司其他综合收益。科济药业具体情况请详见其在港交所发布的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK1587","BK0077","BK1585","02171","300181","BK0114","BK0236","BK0042","BK1161","BK1574","002173","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117284603","title":"科济药业-B回购27万股股份，耗资约406.03万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117284603","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117284603?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:14","pubTimestamp":1783433645,"startTime":"0","endTime":"0","summary":"公司公告显示，2026年7月2日根据此前已获批准的股份回购计划，注销了于2025年10月21日及23日购回的45.5万股股份，约占当时已发行股本的0.077%，回购价格为每股16.85港元；同时注销了59万股库藏股份，并向根据首次公开发行后购股权计划行使购股权的参与人合共发行6000股普通股，每股发行价15.17港元，约占当时已发行股本的0.001%。本次回购及股份变动完成后，截至2026年7月7日，公司已发行股本为5.94226998亿股，库藏股份数量为722.8万股，总股份数目为6.01454998亿股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科济药业-B回购27万股股份，耗资约406.03万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649935886","title":"科济药业-B(02171.HK)7月7日斥资406.03万港元回购27万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649935886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649935886?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:13","pubTimestamp":1783433597,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02171","BK1161","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154587339","title":"科济药业-B2026年6月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1154587339","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154587339?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:51","pubTimestamp":1783425102,"startTime":"0","endTime":"0","summary":"科济药业控股有限公司于2026年7月7日公布截至2026年6月30日的月度股份变动报告。报告显示，公司本月内未发生新增发行、库藏股变动或注销，整体股本维持稳定。公司注册股本截至本期末仍为200,000,000,000股，面值每股USD 0.00000025，总注册股本约USD 50,000，较上月底无变化。已发行普通股为594,675,998股，另有7,818,000股为库存股份，合计602,493,998股，与上月底持平。此前公司在2025年10月购回的455,000股普通股截至2026年6月30日仍未注销。该月报由执行董事李宗海签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197681851","title":"异动解读｜科济药业-B盘中下跌5.13%，管线战略转向引发市场分歧叠加板块整体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1197681851","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197681851?lang=zh_cn&edition=full","pubTime":"2026-07-07 11:02","pubTimestamp":1783393330,"startTime":"0","endTime":"0","summary":"7月7日，科济药业-B盘中下跌5.13%，报15.18港元/股，成交额1753.96万港元。消息面上，公司创始人李宗海近日公开表示，在造出全球首个实体瘤CAR-T产品后，决定不再布局自体型新管线，研发重心将全面转向通用型CAR-T疗法。这一战略转向引发市场对公司近中期自体CAR-T商业化天花板的担忧。板块层面，当日生物科技板块整体承压，荣昌生物跌4.1%、百济神州跌2.41%、康方生物跌1.96%，行业联动加剧个股调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649131916","title":"专访科济药业李宗海：“造出全球首个实体瘤CAR-T产品后，我决定不再布局自体型新管线”","url":"https://stock-news.laohu8.com/highlight/detail?id=2649131916","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649131916?lang=zh_cn&edition=full","pubTime":"2026-07-05 19:42","pubTimestamp":1783251770,"startTime":"0","endTime":"0","summary":"6月25日，科济药业联合创始人、董事会主席、首席执行官兼首席科学官李宗海在北京参加细胞治疗行业论坛，当天下午，科济药业是全场焦点。3天前，这家中国公司拿下全球首款针对实体瘤的CAR-T（嵌合抗原受体T细胞免疫疗法）细胞治疗产品。身为公司灵魂人物的李宗海，成为会场最忙碌的“被围者”。面对持续不断的添加微信好友的申请，他和往常一样几乎照单全收，“（如果）摆个架子多不好意思”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607053794290285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607053794290285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4022","BK1574","CAR","BK4230","02171","BK1161","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139436007","title":"异动解读｜科济药业-B盘中上涨5.14%，回购计划与板块联动持续提振反弹动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1139436007","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139436007?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:13","pubTimestamp":1783055590,"startTime":"0","endTime":"0","summary":"7月3日，科济药业-B盘中上涨5.14%，报15.95港元/股，成交额4386.01万港元。该计划持续为市场信心提供支撑。此外，当日生物科技板块整体走强，康方生物涨4.85%、三生制药涨4.8%、科伦博泰生物涨4.19%、百济神州涨3.09%，板块联动效应助推个股延续反弹。此前公司全球首款实体瘤CAR-T产品恺力美获批上市后股价连续回调，回购计划叠加板块回暖为短期走势提供修复动能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166793389","title":"异动解读｜科济药业-B盘中上涨5.19%，回购计划与板块联动共振延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1166793389","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166793389?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:11","pubTimestamp":1782976287,"startTime":"0","endTime":"0","summary":"7月2日，科济药业-B盘中上涨5.19%，报15.0港元/股，成交额6943.42万港元。此外，当日生物科技板块整体走强，康方生物涨7.78%、科伦博泰生物涨7.7%、三生制药涨7.34%、信达生物涨6.78%，板块联动效应助推个股延续反弹。此前公司全球首款实体瘤CAR-T产品恺力美获批上市后股价连续回调，回购计划叠加板块回暖为短期走势提供修复动能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187413060","title":"异动解读｜科济药业-B盘中上涨6.31%，回购计划叠加板块回暖提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1187413060","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187413060?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:14","pubTimestamp":1782699291,"startTime":"0","endTime":"0","summary":"6月29日，科济药业-B盘中上涨6.31%，报13.93港元/股，成交额3484.46万港元。此前该股在全球首款实体瘤CAR-T产品恺力美获批上市后连续四日下跌，累计跌幅超20%，回购计划的推出对市场信心形成一定支撑。当日生物科技板块整体走强，康方生物涨7.86%、三生制药涨6.73%、信达生物涨5.46%，板块联动效应亦助推个股反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144638759","title":"港股直击 | 董事会批准股份回购计划，科济药业-B午后走高超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144638759","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144638759?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:47","pubTimestamp":1782452837,"startTime":"0","endTime":"0","summary":"科济药业-B( $科济药业-B(02171)$ )午后拉升超3%，截至发稿，升2.9%，报12.78港元，成交额9608.51万港元。科济药业午间公布，董事会已批准一项股份购回计划，自2026年6月25日起至下一届股东周年大会结束为止，在公开市场上购回不超过约3012万股，即相当于截至2026年5月31日已发行股份总数的约5%。股份购回所用资金来自非IPO募集资金，其中包括业务发展收入、利息收入及其他补贴。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/c0570689f988238b492caefa22fe8d8d","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c0570689f988238b492caefa22fe8d8d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.062},{"period":"1month","weight":-0.1088},{"period":"3month","weight":-0.3702},{"period":"6month","weight":-0.086},{"period":"1year","weight":-0.3844},{"period":"ytd","weight":0.0094}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004248},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}